Pharmacologic Management of Pattern Hair Loss

This study found that flutamide at 250 mg daily modestly improved hair thinning in premenopausal women with hyperandrogenic alopecia over one year, while cyproterone acetate and finasteride were not effective.

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.

This case study reports a 66-year-old woman developing shortness of breath while taking 50 mg/day of cyproterone acetate for androgenetic alopecia, a complication not previously documented in women with this condition.

Finasteride treats hair loss but may affect prostate cancer detection.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This article reviews expert opinions on combining pharmacologic treatments like minoxidil with hair transplantation, reporting improved hair density and regrowth in patients with partially functioning follicles.

In this study, depression was more common among women with androgenetic alopecia, while men showed higher levels of anxiety, aggressiveness, and a lack of adherence to treatment.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This study found that topical fluridil increased the anagen hair percentage in men with androgenetic alopecia without causing irritation or systemic absorption over 9 months.

This review discusses female pattern hair loss, emphasizing its complex causes and the limited treatment options available, and reports no new clinical results.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

Hair loss in women is genetic, diagnosed by examination and biopsy, and treated with minoxidil, finasteride, or transplantation.

This review discusses common hair loss conditions and explores how advancements in hair follicle biology might lead to more effective treatments but reports no new results.

FPHL affects hair density and diameter, causing visible hair loss in older women.

Hair loss in women is common, starts in late 20s, and affects 30% of women over 50.

This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.

In this study, 1% procyanidin B-2 tonic significantly increased the number of total and terminal hairs on the scalp of male participants compared to a placebo after 6 months of use.

In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.

This article discusses the importance of focusing on prevention rather than regrowth in managing male pattern hair loss but reports no new clinical results.

This article discusses the medical management of male pattern hair loss and reports no new clinical findings.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

Finasteride 1mg helps reverse hair miniaturization in men and postmenopausal women.

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This study found that minoxidil increased 17ß-hydroxysteroid dehydrogenase activity by nearly 40% in dermal papilla cells from balding scalps but not in nonbalding scalp cells or dermal fibroblasts.

Both drugs lower DHT levels, with GI198745 being more effective.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

Genetics and hormones cause hair loss; finasteride treats it safely.

This study found that 2% ketoconazole shampoo improved hair density and anagen follicle proportion in androgenic alopecia similarly to minoxidil treatment, suggesting a potential role for Malassezia in inflammation.

Male pattern hair loss negatively affects quality of life, but drug treatments can help.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study demonstrated that high oral doses of finasteride caused external genital abnormalities in male rhesus monkey fetuses, but intravenous doses did not lead to abnormalities.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This study found that the prevalence of personality disorders in individuals with androgenetic alopecia was significantly higher than in the general population, irrespective of gender.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.

This study found that women with androgenetic alopecia reported more psychosocial problems and lower self-esteem than women with non-visible skin conditions and men with androgenetic alopecia, which they attributed to their hair loss.

Young men with male pattern baldness lose hair density over time without treatment.

Minoxidil promotes hair growth in women with early-stage alopecia.

This study found that using 2% topical minoxidil before and after hair transplantation may improve graft outcomes by reducing initial shedding in patients with androgenetic alopecia.

This study found that both 2% and 3% topical minoxidil were more effective than placebo in promoting hair growth for men with male pattern baldness over 12 months.

This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

This study observed that two out of twelve patients showed hair growth without the usual shedding after hair transplant surgery when treated with topical minoxidil, suggesting its potential as an adjunctive therapy during recovery.

Minoxidil promotes hair growth in male pattern baldness.

This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.

This review discusses the biology of antiandrogens and highlights available bioassay models to predict their therapeutic effects on human skin, reporting no new clinical results.